End Brain Cancer Initiative Releases Next-Generation Sequencing Cancerous Brain Tumor/Cancer Patient and Caregiver Guide

SEATTLE, WA, UNITED STATES, November 10, 2026 /EINPresswire.com/ — The End Brain Cancer Initiative (EBCI) has released “Next-Generation Sequencing (NGS) Biomarker and Fusion Testing: Targeted Therapy for Brain Tumors/Cancers,” a free patient and caregiver educational guide. This guide was made possible with sponsorship by Jazz Pharmaceuticals and Servier.

Next-Generation Sequencing (NGS) is a powerful laboratory technology that reads the genetic code of a patient’s tumor. It looks for specific changes called mutations, alterations, or biomarkers in the DNA or RNA of the cancer cells. These changes drive the tumor’s growth. By identifying them, doctors can match patients to treatments specifically designed to target those changes.

Patients, caregivers, healthcare providers, and members of the public who would like to learn more can access the free guide at https://endbraincancer.org/next-generation-sequencing/. They can also contact Kari Schroeder, EBCI’s Nurse Navigator/Clinical Trial Coordinator, at 425-436-8688 or Kari@EndBrainCancer.org.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit https://www.jazzpharma.com/ for more information.

About Servier
Servier is a global leader in oncology, governed by a non-profit foundation. Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities. Servier invests close to 20% of revenue from brand-name medicines in R&D each year. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time. Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio. For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier.com and Servier.us.

About the End Brain Cancer Initiative
To support/donate to the End Brain Cancer Initiative’s increased access and health delivery for patients, mission, services, and programs, please visit EndBrainCancer.org and make a donation today.

The End Brain Cancer Initiative (EBCI) is a 501(c)3 non-profit patient advocacy organization focused on disease education, awareness, outreach, increasing patient access and improving Standard of Care. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund (CEF), is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with their medical teams. Learn more about the End Brain Cancer Initiative at EndBrainCancer.org.

Dellann Elliott Mydland, End Brain Cancer Initiative, 425-785-8489, Dellann@EndBrainCancer.org

Dellann Elliott Mydland
End Brain Cancer Initiative
+1 4257858489
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
X

Media gallery